Apellis Pharmaceuticals, Inc. (APLS) Earnings History
Profitable13 years of earnings data (2013–2025) · Positive TTM net income
Loading earnings history...
Apellis Pharmaceuticals, Inc. (APLS) Earnings Overview
As of June 21, 2026, Apellis Pharmaceuticals, Inc. (APLS) reported trailing twelve-month net income of $133M, reflecting +111.3% year-over-year growth. The company earned $0.18 per diluted share over the past four quarters, with a net profit margin of 2.2%.
Looking at the long-term picture, APLS's historical earnings data spans multiple years. The company achieved its highest annual net income of $22M in fiscal 2025, representing a new all-time high.
Apellis Pharmaceuticals, Inc. maintains positive profitability with a gross margin of 89.8%, operating margin of 5.5%, and net margin of 2.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), BEAM (-$65M net income, -57.2% margin), AKRO (-$293M net income), APLS has outperformed on profitability metrics. Compare APLS vs RARE →
APLS Earnings vs Peers
Earnings metrics vs comparable public companies
APLS Historical Earnings Data (2013–2025)
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $22M | +111.3% | $55M | $0.18 | 2.2% | 5.5% |
| 2024 | -$198M | +62.6% | -$165M | $-1.60 | -25.3% | -21.1% |
| 2023 | -$529M | +18.9% | -$517M | $-4.45 | -133.3% | -130.4% |
| 2022 | -$652M | +12.6% | -$595M | $-6.15 | -864.7% | -788.4% |
| 2021 | -$746M | -116.4% | -$536M | $-8.84 | -1121.3% | -805.7% |
| 2020 | -$345M | -13.2% | -$214M | $-4.59 | -137.6% | -85.3% |
| 2019 | -$305M | -139.0% | -$288M | $-4.98 | - | - |
| 2018 | -$128M | -150.0% | -$128M | $-2.34 | - | - |
| 2017 | -$51M | -88.0% | -$51M | $-1.49 | - | - |
| 2016 | -$27M | +41.7% | -$27M | $-1.50 | - | - |
| 2015 | -$47M | -331.2% | -$47M | $-2.57 | - | - |
| 2014 | -$11M | -172.3% | -$11M | $-0.60 | - | - |
| 2013 | -$4M | - | -$4M | $-0.86 | - | - |
Download Data
Export APLS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
13+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
APLS — Frequently Asked Questions
Quick answers to the most common questions about buying APLS stock.
What is APLS earnings per share (EPS)?
APLS trailing twelve-month (TTM) diluted EPS is $0.18, reflecting +111.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.
What is Apellis Pharmaceuticals, Inc.'s net income?
Apellis Pharmaceuticals, Inc. (APLS) trailing twelve-month net income is $133M as of 2025. Earnings grew +111.3% year-over-year.
Is APLS profitable?
Yes, APLS is profitable with a TTM net income of $133M and a net profit margin of +2.2%.
What is APLS's earnings growth rate?
APLS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.
What are APLS's profit margins?
Apellis Pharmaceuticals, Inc. net profit margin is +2.2%, operating margin is +5.5%, and gross margin is +89.8%. Below-average margins reflect competitive or cost pressures. Return on Equity is +7.5%.
Is APLS growing earnings?
Yes, APLS earnings are accelerating — EPS growth of +111.3% exceeds the 5-year CAGR of N/A. TTM net income reached $133M. Earnings momentum is strengthening.
What was APLS's best earnings year?
Apellis Pharmaceuticals, Inc.'s highest annual net income on record is $22M, achieved in fiscal year 2025. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.
What were APLS's earnings last quarter?
APLS's most recent reported quarter was Q1 2026. Net income was $19M with diluted EPS of $0.00. For a full breakdown of all quarters, see the quarterly earnings table on this page.